Core biopsies are commonly used in the diagnosis of breast cancer and often are the only sample for providing prognostic and predictive markers prior to neoadjuvant chemotherapy. We retrospectively studied 87 patients with breast cancer to compare the concordance rates for tumor type, grade, estrogen receptor/progesterone receptor (ER/PR), p53 status and Her2/neu by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) between core and excisional biopsy specimens. The histologic type of cancer had a 100% concordance rate between core and excisional biopsy specimens. The concordance rate of modified Bloom-Richardson score between core and excisional biopsy specimens was 77%, ER was 95%, PR was 89%, and p53 was 86%. The concordance rate for Her2/neu by IHC was 96% and that for FISH was 100% between the core and excisional biopsy specimens. Although breast cancer may have heterogeneous histological and immunohistochemical findings, our study shows that relatively high concordance rates can be obtained when comparing core and excisional biopsy specimens.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.breast.2005.06.004DOI Listing

Publication Analysis

Top Keywords

core excisional
20
excisional biopsy
20
biopsy specimens
20
breast cancer
16
concordance rate
12
concordance rates
8
core
7
biopsy
6
cancer
5
concordance
5

Similar Publications

Percutaneous biopsy is the standard of care for breast lesions, except nipple lesions which are primarily biopsied by excision due to perceived risks of pain and bleeding. However, excisional biopsy of nipple lesion inevitably leads to disfigurement and possible loss of the nipple-areolar complex (NAC), highlighting the need for minimally invasive biopsy techniques. We present our experience of seven patients who underwent ultrasound-guided core biopsy or vacuum-assisted biopsy (VAB) for sampling of clinically occult nipple lesions.

View Article and Find Full Text PDF

Intravascular Ultrasound Assessment of Arterial Dissections Following Rotarex Atherectomy: Results of the iDissection Rotarex Study.

J Soc Cardiovasc Angiogr Interv

September 2024

Cardiovascular Research Department, Midwest Cardiovascular Research Foundation, Davenport, Iowa.

Background: There are limited data on the mechanism of the Rotarex Rotational Excisional Atherectomy System in treating femoropopliteal arterial disease. The Rotarex iDissection study is a prospective, single center study evaluating the extent of excision and dissection in de novo and restenotic (not in-stent) lesions of the femoropopliteal arteries in symptomatic peripheral arterial disease patients.

Methods: Consecutive patients with symptomatic peripheral arterial disease were prospectively enrolled in the Rotarex iDissection study at a single US center after obtaining informed consent.

View Article and Find Full Text PDF

Previously healthy Caucasian female in her 30s initially presented for progressively enlarging right-sided cervical lymphadenopathy with associated sore throat. After she completed 2 antibiotic regimens for presumed infection with no relief, a CT Neck with contrast was obtained which demonstrated multiple pathologic lymph nodes, the largest lymph node demonstrating central necrosis. Patient underwent fine needle aspiration with Otolaryngology, as well as core needle biopsy with Interventional Radiology, both of which were nondiagnostic.

View Article and Find Full Text PDF

Benign and malignant breast lesions in children and adolescents are rare compared to adults. Most tumors are benign. Malignant breast lesions are extremely rare.

View Article and Find Full Text PDF

Background Breast cancer is the most frequently diagnosed cancer in women worldwide, accounting for more than one in ten new cancer cases each year. It ranks as the second leading cause of cancer-related mortality among women. The majority of patients present with palpable breast lumps.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!